Cite
MLA Citation
H Miles Prince et al.. “Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.” Lancet, vol. 390, no. 10094, 2017, pp. 555–566. http://access.bl.uk/ark:/81055/vdc_100049765650.0x000005